Dopamine D1/D5 Receptor Antagonists with Improved
Dopamine D1/D5 Receptor Antagonists with Improved Pharmacokinetics: Design, Synthesis, and Biological Evaluation of Phenol Bioisosteric Analogues of Benzazepine D1/D5 Antagonists Wen-Lian Wu , Duane A. Burnett , Richard Spring , William J. Greenlee , Michelle Smith , Leonard Favreau , Ahmad Fawzi , Hongtao Zhang , and Jean E. Lachowicz
The Dopamine D5 receptor contributes to activation
Interestingly, the D5 receptor is expressed in 88% of cholinergic interneurons (CINs) while only 17% of them express the D1 receptor and none express D3 or D4 receptor 13,14. Furthermore, CINs
Dopamine Agonists - StatPearls - NCBI Bookshelf
Ergot derivatives, older dopamine agonists, interact not only with dopamine D1 and D2 receptors but many other neurotransmitter receptors such as serotonin and adrenergic receptors. Newer dopamine agonists, which are non-ergot agents, have a high affinity to dopamine D2 and D3 receptors. Amantadine is not a dopamine agonist.
SCH 23390: the first selective dopamine D1-like receptor
SCH 23390: the first selective dopamine D1-like receptor antagonist SCH 23390, the halobenzazepine (R)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5- tetrahydro-1H-3-benzazepine, is a highly potent and selective dopamine D1-like receptor antagonist with a K(i) of 0.2 and 0.3 nM for the D1 and D5 dopamine receptor subtypes, respectively.
Dopamine D1/D5 receptors mediate informational saliency that
In light of these observations, we propose that D1/D5 receptors gate hippocampal long-term plasticity and memory and are pivotal in conferring the properties of novelty and reward to information being processed by the hippocampus. Keywords: cognition; hippocampus; learning and memory; review; synaptic plasticity. Publication types
